Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
$3.13
+6.8%
$3.33
$1.72
$3.84
$29.42M1.4925,679 shs1,835 shs
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
$56.00
$55.66
$17.15
$56.48
$1.14B2.34301,073 shsN/A
NVH
Novoheart
C$0.53
+1.9%
C$0.53
C$0.26
C$0.72
C$99.98MN/A33,593 shs23,066 shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-0.39%-4.30%-13.87%+14.84%+8.37%
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
0.00%0.00%0.00%0.00%+110.92%
NVH
Novoheart
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
2.2919 of 5 stars
3.53.00.00.01.70.81.3
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
N/AN/AN/AN/AN/AN/AN/AN/A
NVH
Novoheart
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
3.00
Buy$6.0091.69% Upside
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
2.00
HoldN/AN/A
NVH
Novoheart
N/AN/AN/AN/A

Current Analyst Ratings

Latest CIR, NVH, and ACST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/7/2024
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/A$9.14 per shareN/A
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
$786.92M1.45$4.77 per share11.74$7.81 per share7.17
NVH
Novoheart
C$423.50K236.08C$0.07 per share7.46C$0.12 per share4.34

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-$42.43M-$5.08N/AN/AN/AN/A-13.18%-11.32%6/28/2024 (Estimated)
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
$19.39M$1.3740.8819.51N/A3.40%35.32%5.21%N/A
NVH
Novoheart
N/A-C$0.04N/AN/AN/AN/AN/AN/A

Latest CIR, NVH, and ACST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/12/202412/31/2023
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-$0.23-$0.21+$0.02-$0.21N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/AN/A
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
N/AN/AN/AN/AN/A
NVH
Novoheart
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/A
15.19
15.19
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
3.34
2.29
1.46
NVH
Novoheart
27.62
6.13
6.05

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
6.08%
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
96.16%
NVH
Novoheart
N/A

Insider Ownership

CompanyInsider Ownership
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
13.51%
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
1.00%
NVH
Novoheart
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
329.40 million8.13 millionNot Optionable
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
3,06020.39 million20.19 millionOptionable
NVH
Novoheart
N/A188.64 millionN/ANot Optionable

CIR, NVH, and ACST Headlines

SourceHeadline
Building miniature hearts to improve clinical trialsBuilding miniature hearts to improve clinical trials
biotechniques.com - June 22 at 8:37 AM
Leaked Documents Reveal Cybertrucks Glaring Design FlawsLeaked Documents Reveal Cybertruck's Glaring Design Flaws
futurism.com - June 14 at 5:37 PM
067570.KQ - NVH Korea Inc.067570.KQ - NVH Korea Inc.
finance.yahoo.com - June 12 at 1:23 PM
NBA Playoffs: Jokic set for 1st NBA Finals, Heat try to clinch East crownNBA Playoffs: Jokic set for 1st NBA Finals, Heat try to clinch East crown
whio.com - May 26 at 4:32 AM
NBA Playoffs: Nuggets become 1st team to reach this years NBA final fourNBA Playoffs: Nuggets become 1st team to reach this year's NBA final four
wftv.com - May 18 at 2:11 AM
NVH Korea Inc (067570)NVH Korea Inc (067570)
uk.investing.com - February 21 at 1:07 PM
Novoheart Holdings Inc (NVH)Novoheart Holdings Inc (NVH)
investing.com - July 22 at 11:31 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acasti Pharma logo

Acasti Pharma

NASDAQ:ACST
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
CIRCOR International logo

CIRCOR International

NYSE:CIR
CIRCOR International, Inc. designs, manufactures, and distributes flow and motion control products in Europe, the Middle East, Africa, North America, and internationally. The company has a product portfolio of brands serving its customers' demanding applications. It operates through two segments, Aerospace & Defense and Industrial. The Aerospace & Defense segment manufactures and markets control valves, pumps, regulators, fluid controls, pneumatic valves and controls, electro-mechanical controls, electric motors, and other flow control products and subsystems; propeller pumps; actuation systems; MIL-spec butterfly valves and actuators; brushless DC motors; switches; and actuation components and sub-systems. Its products and services are used in the military and defense, commercial aerospace, business and general aviation, and general industrial markets, as well as serves aircraft manufacturers and tier 1 and tier 2 suppliers. This segment offers its products under the CIRCOR Aerospace, Aerodyne Controls, CIRCOR Bodet, CIRCOR Industria, CIRCOR Motors, Hale Hamilton, Leslie Controls, Portland Valve, and Warren Pumps brands. The Industrial segment provides 3 and 2 screw pumps, progressing cavity pumps, specialty centrifugal pumps, and gear metering pumps; automatic recirculation valves; engineered valves; positive displacement pumps; general service control valves; and top and bottom unheading devices and center feed devices for the end-users and original equipment manufacturers, as well as engineering, procurement, and construction companies. This segment offers its products under the Allweiler, DeltaValve, Houttuin, IMO Pump, IMO AB, Leslie Controls, RG Lawrence, RTK, Schroedahl, TapcoEnpro, Tushaco, and Zenith brands. The company markets its solutions directly and through various sales partners to approximately 14,000 customers in approximately 100 countries. CIRCOR International, Inc. was incorporated in 1999 and is headquartered in Burlington, Massachusetts.

Novoheart

CVE:NVH
Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada.